Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

Ivonescimab is the first therapy to achieve statistically significant positive results in a Phase III trial compared with ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPN Preclinical data show ...

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

OnePlus was quick with the Android 15 release. It wrapped up the rollout in February 2025, while millions of Android users ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

Shares of OS Therapies rose 19% to $1.78 in premarket trading Tuesday.